Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

25,120 signal articles · 227 in last 24h · 119,779 total before filter · latest 32m ago
227last 24h
1442last 7d
239● bullish (7d)
159● bearish (7d)
205publishers
AllMacro259Earnings555M&A102Regulatory19Product11Analyst23
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
2 Surging  Stocks Worth Investigating and 1 Facing Headwinds
StockStory16d agoneutral
2 Surging Stocks Worth Investigating and 1 Facing Headwinds

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Bloomberg16d agoneutral
Aramco Sees Oil Refineries Running Flat Out as Buffers Run Thin

(Bloomberg) -- Refineries outside of conflict zones are running at full tilt across the world and there are few shock absorbers left in the system to protect against higher fuel prices, the world’s biggest oil company Saudi Aramco said.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevTaco Bell Met With Michigan on Parasite Weeks Before RecallApple’s New CEO Taps Retired Hardware Executive for Management TeamMamdani Dismisses Business Leaders Advising NYC’s Mayor’s

Merck Shares Advance After Strong Second-Quarter Earnings and Higher Revenue Outlook
InvestorsHub16d agoneutral
Merck Shares Advance After Strong Second-Quarter Earnings and Higher Revenue Outlook

Merck (NYSE:MRK) shares moved higher in pre-market trading after the pharmaceutical company reported second-quarter 2026 results that exceeded Wall Street expectations and raised its full-year revenue guidance. Although Merck reduced its adjusted earnings outlook to reflect acquisition-related charges, investors welcomed the stronger-than-expected quarterly performance and improved sales forecast.

TransDigm (NYSE:TDG) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations
StockStory16d agoneutral
TransDigm (NYSE:TDG) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations

Aerospace and defense company TransDigm (NYSE:TDG) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 22.5% year on year to $2.74 billion. The company’s full-year revenue guidance of $10.51 billion at the midpoint came in 1.3% above analysts’ estimates. Its non-GAAP profit of $10.87 per share was 5.2% above analysts’ consensus estimates.

Bloomberg16d agoneutral
Polymarket Seeks More Than $20 Billion Valuation in Funding Round

(Bloomberg) -- Polymarket is seeking to raise capital at a valuation of more than $20 billion, months after it closed an earlier round with new investment from hedge fund D.E. Shaw & Co.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevTaco Bell Met With Michigan on Parasite Weeks Before RecallApple’s New CEO Taps Retired Hardware Executive for Management TeamMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundChina’s AI Blitz Creates ‘Death Zone’ for Riv

Coupang (CPNG) Could Be 54% Undervalued Ahead Of Its August 4 Earnings
Simply Wall St.16d agoneutral
Coupang (CPNG) Could Be 54% Undervalued Ahead Of Its August 4 Earnings

Why Coupang’s upcoming earnings matter for investors Coupang (CPNG) is set to report Q2 2026 results after the close on August 4, with the market watching how a projected 6.2% revenue increase compares with last year’s 16.4% pace. See our latest analysis for Coupang. Coupang’s share price has been under pressure in 2026, with a year to date share price return down 29.74% and a 1 year total shareholder return down 45.08%. However, the 7 day share price return of 6.35% suggests some short term...

Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo
Simply Wall St.16d agoneutral
Pfizer (PFE) Reports Positive Phase 3 LITFULO Data In Vitiligo

Pfizer (NYSE:PFE) reported positive Phase 3 results for LITFULO in nonsegmental vitiligo. The company plans to pursue global regulatory filings for LITFULO as an oral therapy for this autoimmune skin disease. For investors watching Pfizer, this update highlights an area of its late stage pipeline that sits outside its COVID and oncology businesses. Nonsegmental vitiligo is a chronic condition with limited systemic treatment options, so additional clinical data around efficacy and safety is...

Snap (SNAP) Is Up 5.7% After Strong Q2 Revenue, Narrower Losses And AR Push - What's Changed
Simply Wall St.16d agoneutral
Snap (SNAP) Is Up 5.7% After Strong Q2 Revenue, Narrower Losses And AR Push - What's Changed

Snap Inc. has just reported its second-quarter 2026 results, with revenue rising to US$1,598.99 million from US$1,344.93 million a year earlier and net loss narrowing to US$163.96 million from US$262.57 million, supported by gains in advertising and subscription revenue plus positive free cash flow. The quarter also marked continued user and monetization progress, as daily active users reached 493 million and average revenue per user climbed to US$3.25, while Snap pressed ahead with AI...

AstraZeneca (LSE:AZN) Is In Merger Talks With Bristol Myers For $400 Billion
Simply Wall St.16d agoneutral
AstraZeneca (LSE:AZN) Is In Merger Talks With Bristol Myers For $400 Billion

AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. The transaction, if completed, would rank among the largest in the sector and could significantly affect competitive positions in oncology. Regulators are expected to review any agreement closely due to overlapping product portfolios. AstraZeneca is a global pharmaceutical company with a significant focus on...

Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More
24/7 Wall St.16d agoneutral
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and More

Pre-Market Stock Futures: Futures are trading higher after a solid start to August, with all major indices finishing higher on Monday. The President tapping the brakes on attacks on Iran and a return to the negotiating table, combined with massive technology earnings and tumbling oil prices, was just the ticket for traders and investors to ... Here Are Tuesday’s Top Wall Street Analyst Research Calls: Apple, CoreWeave, eBay, Exxon Mobil, Intuit, Nebius Group, Palantir Technologies, SK hynix, and

Diamondback Energy Reveals Brutal Truth: High Oil Prices Are Here to Stay
24/7 Wall St.16d agoneutral
Diamondback Energy Reveals Brutal Truth: High Oil Prices Are Here to Stay

For much of the past decade, investors treated oil price spikes as temporary disruptions that eventually faded. That assumption is becoming harder to defend. The Iran war has fundamentally changed the balance between global supply and demand, and the world’s oil market is still struggling to recover. Before hostilities erupted, West Texas Intermediate (WTI) crude ... Diamondback Energy Reveals Brutal Truth: High Oil Prices Are Here to Stay

Block’s (XYZ) AI Reset Signals New Earnings Phase
Insider Monkey16d agoneutral
Block’s (XYZ) AI Reset Signals New Earnings Phase

Third Point Management, a New York-based investment advisor, released its second-quarter 2026 investor letter. A copy is available to download here. Third Point’s flagship Offshore Fund returned 7.7% in Q2 2026, outperforming the hedge fund index but trailing broader equity benchmarks. Second Quarter returns benefited from strong performance in semiconductors, memory, semiconductor equipment, power infrastructure, […]